Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Accumulated Expenses (2016 - 2025)

Ocular Therapeutix (OCUL) has 13 years of Accumulated Expenses data on record, last reported at $43.8 million in Q4 2025.

  • For Q4 2025, Accumulated Expenses rose 24.83% year-over-year to $43.8 million; the TTM value through Dec 2025 reached $43.8 million, up 24.83%, while the annual FY2025 figure was $43.8 million, 24.83% up from the prior year.
  • Accumulated Expenses reached $43.8 million in Q4 2025 per OCUL's latest filing, up from $13.1 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $43.8 million in Q4 2025 and bottomed at $3.5 million in Q1 2022.
  • Average Accumulated Expenses over 5 years is $16.8 million, with a median of $13.3 million recorded in 2021.
  • Peak YoY movement for Accumulated Expenses: crashed 74.07% in 2022, then surged 331.15% in 2023.
  • A 5-year view of Accumulated Expenses shows it stood at $6.6 million in 2021, then rose by 13.82% to $7.5 million in 2022, then skyrocketed by 281.76% to $28.7 million in 2023, then grew by 22.5% to $35.1 million in 2024, then grew by 24.83% to $43.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Expenses were $43.8 million in Q4 2025, $13.1 million in Q3 2025, and $34.4 million in Q2 2025.